The 2MM Team #VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM) December 25, 2020 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print Check out the original article from the Lancet Haematology here. RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract CASSIOPEIA Part 1: Bortezomib, Thalidomide, and Dexamethasone with Daratumumab (D-VTd) May Improve Quality of Life Post-Consolidation in Newly Diagnosed, Transplantation-Eligible Multiple Myeloma (MM)... #VisualAbstract: Low dose edoxaban prevents stroke in elderly patients with atrial fibrillation
